Thus, Flt3 is applied to manipulate DCs to produce high-efficiency immunotherapy in vitro and in vivo.6 DCs can take up dead tumor cells,12 pathogens, apoptotic cells, and infected cells and process antigens derived from these particles into peptides, and load these peptides into major histocompatibility complex (MHC) class I and MHC class II molecules.11 The gene discussed is HLA-C; the disease is neoplasm.